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Abstract
Background: The purpose of this case-control study was to compare the prognoses of women with stage III
mucinous ovarian carcinoma (MOC) who received maximal or optimal cytoreduction followed by paclitaxel
plus carboplatin chemotherapy to those of women with stage III serous epithelial ovarian cancer (EOC) treated
in the similar manner.
Methods: We performed a multicenter, retrospective review to identify patients with stage III MOC at seven
gynecologic oncology departments in Turkey. Eighty-one women with MOC were included. Each case was
matched to two women with stage III serous EOC in terms of age, tumor grade, substage of disease, and extent of
residual disease. Survival estimates were measured using Kaplan-Meier plots. Variables predictive of outcome were
analyzed using Cox regression models.
Results: With a median follow-up of 54 months, the median progression-free survival (PFS) for women with stage III
MOC was 18.0 months (95% CI; 13.8–22.1, SE: 2.13) compared to 29.0 months (95% CI; 24.04–33.95, SE: 2.52)
in the serous group (p = 0.19). The 5-year overall survival rate of the MOC group was significantly lower than
that of the serous EOC group (44.9% vs. 66.3%, respectively; p < 0.001). For the entire cohort, presence of multiple
peritoneal implants (Hazard ratio [HR] 2.39; 95% confidence interval [CI], 1.38–4.14, p = 0.002) and mucinous histology
(HR 2.28; 95% CI, 1.53–3.40, p < 0.001) were identified as independent predictors of decreased OS.
Conclusion: Patients with MOC seem to be 2.3 times more likely to die of their tumors when compared to women
with serous EOC.
Keywords: Analyses, survival, Epithelial ovarian cancer, Mucinous adenocarcinoma, Serous cystadenocarcinoma
Introduction
Primary mucinous ovarian carcinoma (MOC) represents
a biochemically and genetically distinct subgroup of
epithelial ovarian cancer (EOC) [1]. MOC accounts for
3% [2] to 10% [3] of all ovarian carcinomas. Most
patients with MOC are diagnosed at an early stage and
therefore it confers a favorable prognosis [3]. However,
once the disease is advanced, mucinous histology has a
poorer outcome compared to the other histologic sub-
groups [4–7].
Mucinous histology has consistently been reported as
an independent adverse prognostic factor in advanced
EOC [6, 8, 9] and the outcomes of MOCs are signifi-
cantly different from EOCs with serous histology [10].
The reason for poor prognosis of advanced MOC has
been suggested to be either the aggressive biology of
mucinous tumor or chemoresistance or both [9, 11, 12].
Approximately 14% of all MOCs are diagnosed as stage
III disease [7]. Response rates to standard platinum-based
chemotherapy are low (12.5–38.5%) among women with
MOC, and debulking to minimal or no residual disease
(RD) remains the standard of care [13]. It has been re-
ported that overall survival (OS) is 3.8 fold increased in
patients who have received optimal cytoreductive surgery
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(CRS) compared to the patients who have had suboptimal
cytoreduction [14].
We wondered whether the worse prognosis associated
with mucinous histology is also valid when age, tumor
grade, substage of disease, and extent of RD are matched
with serous histology in women with stage III EOC who
have undergone primary CRS followed by standard
intravenous paclitaxel plus carboplatin chemotherapy.
Given the low frequency of stage III MOC, a multicenter
effort was essential in order to achieve an adequate number
in this case-control study. The objective of this retrospect-
ive, multicenter study was to compare prognostic factors of
women with stage III MOC to those of women with stage
III serous EOC treated in the same fashion.
Methods
After Institutional Review Board approval (IRB Approval
Number: 05, Date: November 7th 2017), institutional
databases for EOC were utilized to identify eligible cases.
The databases consisted of individual patients with EOC
who underwent upfront surgery between January 1998
and December 2016 at seven gynecologic oncology de-
partments in Turkey. All patients provided an informed
consent at admission for storage of their clinical infor-
mation and for research use of their clinical data.
The case group consisted of EOC patients with histo-
pathologically confirmed Stage III [15] MOC. We included
only the patients with optimal or maximal CRS in the
upfront surgery. We excluded the patients who had
RD greater than 1 cm. Since the case group included
only women having pure mucinous histology; women
with mixed histologies including mucinous tumors com-
bined with endometrioid, serous, clear-cell, and/or other
histologic types were excluded. The patients who received
neoadjuvant chemotherapy, women with synchronous
malignancies, and those with incomplete medical records
were also excluded from the study.
Using a dependent random sampling method, each
case was matched to two patients with serous EOC from
a series of 783 women who had undergone maximal or
optimal CRS (RD ≤ 1 cm) followed by paclitaxel and car-
boplatin combination chemotherapy for the same period.
In the case and control groups, pairs were matched in
terms of age at diagnosis (+/− 10 years), year of diagnosis,
grade of the tumor (grade 1, 2, or 3), substage (stage IIIA1,
IIIA2, IIIB, and IIIC), and extent of RD (maximal vs. opti-
mal debulking). While selecting the patients in the control
group, we were blinded to the outcomes of the patients in
order to prevent possible patient selection bias.
The following clinical data were extracted from patients’
medical, surgical, pathology, and chemotherapy reports:
demographic characteristics, preoperative serum cancer
antigen 125 (CA 125) levels, type and date of surgical
procedure, presence of multiple (≥2) peritoneal implants,
ascites status, results of peritoneal washings (negative or
positive), appendiceal involvement, omental involvement,
size of RD after surgery, stage of disease, time to recur-
rence, length of follow-up and survival. Pathologic charac-
teristics of the disease were abstracted from original
pathology reports. Data were collected from departments
with an online standardized form.
Gynecologic oncologists performed all of the operations
with the aim of achieving complete cytoreduction. After
primary CRS, RD was recorded according to the assess-
ment by the surgical team. Retroperitoneal lymph node
dissection was performed after completion of intraabdom-
inal cytoreduction. Number of total lymph nodes (LNs)
removed, number of para-aortic LNs removed, and num-
ber of pelvic LNs removed and number of metastatic LNs
were noted.
All pathologic specimens of the upfront surgery were
evaluated and interpreted by expert gynecologic patholo-
gists of the participating institutions with experience in
gynecological malignancies but were not reviewed centrally
in the current study.MOC was diagnosed after examination
of permanent sections. Immunuhistochemical study
was performed in women where metastatic tumors could
not be excluded. With careful exclusion of noninvasive
and metastatic mucinous tumors, women who had final
pathologic diagnoses as “primary MOCs” were included in
the case group.
The World Health Organization (WHO) criteria were
used for histologic classification of the tumors [16, 17].
Architectural grading was defined by standard Inter-
national Federation of Gynecology and Obstetrics (FIGO)
criteria. All tumors were staged according to the FIGO
staging system, which was revised in 2014 [15]. In patients
treated before 2014, stage was adapted to the FIGO 2014
staging system retrospectively using surgical and patho-
logic assessment.
All patients (cases and controls) received adjuvant
chemotherapy. The standard first line chemotherapy
protocol included paclitaxel 175 mg/m2 plus carboplatin
at the dose of area under curve (AUC) 5 or 6 every
21 days for 6 cycles. Targeted agents (i.e. bevacizumab)
were not included in the first line chemotherapy. Platinum
refractory disease was defined as disease progression on
first-line platinum based regimen, whereas platinum resist-
ant disease included patients with tumor progression within
6 months of completion of platinum based chemotherapy.
We followed-up the patients quarterly for the first
2 years, biannually until 5 years, and annually thereafter.
The follow-up visits included physical and gynecologic
examinations, and serum CA 125 measurements. Each
patient was assessed for relapse with imaging studies
and serum CA 125 measurements. Treatment of the re-
currences (surgery and/or chemotherapy) was applied
according to the institutional practices at that time.
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Survival data were last calculated on 31st December
2016. The survival status of the patients was determined
as alive or dead at the time of the last follow-up visit.
Survival status for all the subjects was confirmed by social
security death index search.
Maximal cytoreduction was defined as no visible RD
left in-situ (microscopic RD) after primary CRS. Optimal
cytoreduction was defined as a RD less than or equal to
1 cm maximal diameter of the largest tumor deposit at
the end of the primary surgery. Similarly, suboptimal
cytoreduction was defined as > 1 cm of RD. Lymphade-
nectomy was defined as the dissection of pelvic and
para-aortic LN’s at the same time. Progression-free sur-
vival (PFS) was defined as the time, in months, from the
primary surgery to the documented recurrence with
clinical examination and/or radiologic imaging; or death
from any cause, whichever occurred first, or the date of
last follow-up for patients remaining alive without recur-
rence. Patients who had no active disease at the last con-
tact were censored in the PFS analysis. Overall survival
(OS) was defined as the time, in months, between the
date of primary surgery to the date of death or the last
follow-up. Surviving patients were censored at their last
known follow-up.
Survival curves were generated using Kaplan-Meier
plots and survivals were compared using the log-rank
test. The chi-squared test was used for nominal vari-
ables. For continuous variables, Student’s t-test and the
Mann-Whitney U tests were used for continuous vari-
ables with and without normal distribution, respectively.
Cox logistic regression models were used to determine
co-variates affecting survival, and presented as hazard
ratios (HRs) with 95% confidence interval (CI), un-
adjusted or adjusted for all factors. All variables with a p
value < 0.05 in the univariate analysis were included in
the multivariate analysis. All statistical analyses were
performed with the SPSS software version 23.0 (IBM
Corp., Armonk, NY, USA). A p value < 0.05 was consid-
ered statistically significant.
Results
One hundred and sixty-four women were identified with
a postoperative pathology-proven diagnosis of stage III
primary MOC at seven participating centers during the
study period. We excluded 74 women who had subopti-
mal CRS, six women who received neoadjuvant chemo-
therapy, one with synchronous breast cancer and two
women with incomplete medical records. Therefore, 81
women with stage III MOC were included in the final
analysis. These 81cases were compared to 162 controls
with serous EOC who had maximal or optimal CRS
followed by paclitaxel plus carboplatin combination
chemotherapy.
Table 1 demonstrates the demographic and clinico-
pathologic characteristics of the study population. Age,
menopausal status, presence of multiple peritoneal im-
plants, tumor grade, substage of disease, positive periton-
eal cytology, extent of RD, appendiceal involvement, and
omental involvement were similar between the cases and
controls. Patients with serous EOC were more likely to
have elevated median baseline serum CA 125 levels
(514 IU/ml vs. 126 IU/ml; p = 0.022), ascites (125/162
vs. 42/81; p < 0.001), and positive retroperitoneal LNs
(116/162 vs. 21/81; p < 0.001). The median number of
total LNs harvested, the median number of pelvic LNs
removed were significantly higher in the serous EOC
patients when compared to women with MOC as well
as the median number of para-aortic LNs removed (49
vs. 34; p < 0.001, 32 vs. 24; p = 0.003, and 15 vs. 11; p <
0.001, respectively). In both of the groups, stage IIIA1,
IIIA2, IIIB and IIIC disease were noted in 16.1%, 7.4%,
16.0% and 60.5%, respectively.
With a median follow-up of 54 months (range, 5–
216 months), the median PFS for women with stage III
MOC was 18.0 months (95% CI; 13.8–22.1, SE: 2.13)
compared to 29.0 months (95% CI; 24.04–33.95, SE:
2.52) in the serous EOC group (p = 0.19) (Fig. 1). The
5-year OS rate of the MOC group was significantly lower
than that of the serous EOC group (44.9% vs. 66.3%, re-
spectively; p < 0.001) (Fig. 2).
Platinum refractory disease was detected more frequently
in the mucinous group (n = 18, 22.2%) than in the serous
group (n = 9, 5.5%) (p < 0.001). However, the number of
women with platinum resistant disease was comparable
between the mucinous and serous groups (n = 12 [14.8%]
and n = 21 [12.9%], respectively, p = 0.69).
For the entire cohort, univariate analysis revealed sub-
stage of disease (stage IIIA1 vs. other stages) (p < 0.001),
positive peritoneal cytology (p = 0.01), appendiceal in-
volvement (p < 0.001), omental involvement (p < 0.001),
and presence of multiple peritoneal implants (p < 0.001)
as significant factors for decreased PFS. In multivariate
analysis, presence of multiple peritoneal implants (HR
2.1, 95% CI 1.40–3.14; p < 0.001) remained as the sole
independent risk factor for decreased PFS.
For the entire cohort, univariate analysis revealed sub-
stage of disease (stage IIIA1 vs. other stages) (p = 0.001),
appendiceal involvement (p < 0.001), omental involvement
(p < 0.001), presence of multiple peritoneal implants (p <
0.001), and mucinous histology (p < 0.001) as significant
factors for decreased OS (Table 2). Multivariate analysis
demonstrated presence of multiple peritoneal implants
(HR 2.39; 95% CI, 1.38–4.14, p = 0.002) and mucinous
histology (HR 2.28; 95% CI, 1.53–3.40, p < 0.001) as inde-
pendent predictors of decreased OS (Table 2).
Finally, 81 patients with stage III MOC were separately
analyzed. Univariate analysis revealed substage of disease
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(stage IIIA1 vs. other stages) (p < 0.001), omental involve-
ment (p = 0.004), and optimal debulking (p < 0.001) as sig-
nificant factors for decreased PFS. In the multivariate Cox
regression model, only maximal CRS (HR 0.48; 95% CI,
0.23–0.97, p = 0.041) was identified as an independent pre-
dictor of increased PFS. For women with stage III MOC,
univariate analysis revealed substage of disease (stage IIIA1
vs. other stages) (p = 0.002), omental involvement (p =
0.008), and optimal debulking (p < 0.001) as significant fac-
tors for decreased OS (Table 3). In multivariate analysis,
only maximal CRS (HR 0.37; 95% CI, 0.16–0.86, p = 0.021)
remained as an independent predictor of increased OS
(Table 3). At the time of reporting, of 81 women with
stage III MOC, 49 (60.5%) were dead whereas 32
(39.5%) were alive. The corresponding figures were found
to be 50 (30.9%) and 112 (69.1%), respectively in the
serous EOC group.
Discussion
Our results indicate that presence of multiple peritoneal
implants and mucinous histology seem to be the inde-
pendent predictors of decreased OS in a cohort of 243
women who have undergone maximal or optimal CRS
and found to have either mucinous or serous stage III
EOC at the end of final pathology report. Patients with
MOC were 2.3 times more likely to die of their tumors
when compared to women with serous EOC.
The retrospective nature of the study and lack of central
pathology review seem to be the major limitations of the
current study. Patients were treated and observed at seven
different gynecologic cancer centers. Therefore, we might
not have presented the clinical outcomes of the recurrent
patients objectively and equally since the treatment of
recurrences was not uniform, and changed according to
the institutional practices at that time.
It has been reported that the clinical behavior of MOC
is distinctly different from serous EOC and the progno-
sis of MOC is worse when compared to other histologies
[6–9, 14, 18–21]. Hess et al. [18] have reported that
MOC has a HR of 2.94 for progression and a HR of 3.08
for death in a study of 27 women with stage III/IV MOC.
Winter et al. [19] reported that mucinous histology was
associated with a worse PFS and OS compared with ser-
ous carcinomas in a study including 34 women with stage
III MOC. In that study, the median PFS was 10.5 months
whereas the median OS was 14.8 months for women with
MOC.
In a meta-analysis consisting of 264 women with stage
III/IV MOC, Mackay et al. [20] reported that patients
with MOC had an increased risk of death (HR 2.66, 95% CI
2.29–3.08) and disease-progression (HR 2.10, 95% CI 1.84–
2.41) compared to those with serous carcinoma. Patients
with mucinous histology had an estimated median PFS of
7.6 months and a median OS of 14.6 months in that
Table 1 Demographic and clinicopathologic characteristics of
the study population (n = 243)
Characteristics MOC Serous EOC
Values, n (%) Values, n (%) p
Age, y (median, range) 53.9 (18–77) 53.4 (28–81) 0.73
Menopausal status
Postmenopausal 49 (60.5%) 98 (60.5%) 1.0
Premenopausal 32 (39.5%) 64 (39.5%) 1.0
CA 125 (IU/ml) (median, range) 126 (4–4891) 514 (8–27,580) 0.022
Grade
1 29 (35.8%) 58 (35.8%) 1.0
2–3 52 (64.2%) 104 (64.2%) 1.0
Stage
IIIA1 13 (16.1%) 26 (16.1%) 1.0
IIIA2 6 (7.4%) 12 (7.4%) 1.0
IIIB 13 (16%) 26 (16%) 1.0
IIIC 49 (60.5%) 98 (60.5%) 1.0
Debulking
Optimal 54 (66.7%) 108 (66.7%) 1.0
Maximal 27 (33.3%) 54 (33.3%) 1.0
Ascites
Present 42 (51.9%) 125 (77.2%) < 0.001
Absent 39 (48.1%) 37 (22.8%)
Peritoneal Cytology
Positive 61 (75.3%) 137 (84.6%) 0.114
Negative 20 (24.7%) 25 (15.4%)
Number of LNs removed
(median, range)
34 (19–96) 49 (21–203) < 0.001
Pelvic LNs 24 (10–75) 32 (10–101) 0.003
Para-aortic LNs 11 (5–54) 15 (5–102) < 0.001
Retroperitoneal LN metastases
Present 21 (25.9%) 91 (56.2%) < 0.001
Absent 60 (74.1%) 71 (43.8%)
Appendiceal Involvement
Present 29 (35.8%) 59 (36.4%) 1.0
Absent 52 (64.2%) 103 (63.6%)
Omental Involvement
Present 61 (75.3%) 113 (69.8%) 0.451
Absent 20 (24.7%) 49 (30.2%)
Peritoneal Involvement
Present 57 (70.4%) 103 (63.6%) 0.318
Absent 24 (29.6%) 59 (36.4%)
Status
Alive 32 (39.5%) 112 (69.1%)
Dead 49 (60.5%) 50 (30.9%)
Follow-up, months (median, range) 21 (1–216) 46 (1–121)
Abbreviations: n Number, LN Lymph node, y year, MOC Mucinous Ovarian
Carcinoma, EOC Epithelial Ovarian Carcinoma, SD Standard Deviation
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Fig. 1 Kaplan Meier Plots for progression free survival of the women with Stage III mucinous (n = 81) and serous (n = 162) ovarian cancer
Fig. 2 Kaplan Meier Plots for overall survival of the women with Stage III mucinous (n = 81) and serous (n = 162) ovarian cancer
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meta-analysis. Bamias et al. [21] reported the median OS as
15.0 months for 21 women with stage III/IV MOC com-
pared to 45.0 months for 389 women with stage III/IV
ovarian high-grade serous carcinoma. In a case-control
study, Karabuk et al. [14] have reported the median PFS
and OS as 7.0 and 35.0 months, respectively, for 50 women
with stage III/IV MOC. The authors concluded that the risk
of death for MOC patients was significantly higher than
that of serous EOC patients (HR 2.14, 95% CI 1.34–3.42).
In the current study, we have found out the median PFS
Table 2 Univariate and multivariate analyses for overall survival
in the entire cohort (stage III mucinous [n = 81] and serous
[n = 162] ovarian carcinoma)
Univariate
analysis OSa
N of events (%)
p Multivariateanalysis
HR CI 95% p
Age, y
< 52 36/118 (61.7%) 0.163
≥ 52 47/125 (56.7%)
Menopausal Status
Premenopausal 33/96 (56.6%) 0.89
Postmenopausal 50/147 (60.5%)
Ca-125(IU/ml)
< 310 46/121 (56.2%) 0.089
≥ 310 37/122 (62.2%)
Grade
1 33/87 (55.1%) 0.74
2–3 50/156 (61.5%)
Ascites
Present 62/167 (56.2%) 0.371
Absent 21/76 (66%)
Retroperitoneal LN metastases
Present 44/112 (39.2%) 0.646
Absent 55/131 (41.9%)
Peritoneal cytology
Positive 73/198 (56.5%) 0.215
Negative 10/45 (71.8%)
Stage
IIIA1 6/39 (78.4%) 0.001
IIIA2, IIIB, IIIC 77/204 (55.6%)
Appendiceal Involvement
Present 41/88 (45%) < 0.001
Absent 42/155 (66.9%)
Omental Involvement
Present 71/174 (52%) < 0.001
Absent 12/69 (77.6%)
Peritoneal Involvement
Present 67/160 (49.2%) < 0.001 2.39 1.38–4.14 0.002
Absent 16/83 (76.9%)
Histologic Subtype
Mucinous 41/81 (44.9%) < 0.001 2.28 1.53–3.40 < 0.001
Serous 42/162 (66.3%)
a:5-year overall survival rate
Abbreviations: OS Overall Survival, LN Lymph node, HR Hazard ratio, CI
Confidence interval, y Year, N number
Table 3 Univariate and multivariate analyses for overall survival
in women with stage III mucinous ovarian carcinoma (n = 81)
Univariate
analysis OSa
N of events (%)
p Multivariate analysis
HR CI 95% p
Age, y
< 54 17/39 (52.2%) 0.126
≥ 54 24/42 (38.1%)
Menopausal Status
Premenopausal 15/32 (49%) 0.49
Postmenopausal 26/49 (42%)
Ca-125(IU/ml)
< 126 19/40 (49.2%) 0.42
≥ 126 22/41 (40.4%)
Grade
1 16/29 (36%) 0.98
2–3 25/52 (48%)
Ascites
Present 24/42 (37.4%) 0.174
Absent 17/39 (52.4%)
LN metastases
Present 13/21 (27.9%) 0.433
Absent 28/60 (50.4%)
Peritoneal cytology
Positive 35/61 (36.8%) 0.092
Negative 6/20 (67.7%)
Appendiceal Involvement
Present 18/29 (30.9%) 0.180
Absent 23/52 (51.9%)
Omental Involvement
Present 35/61 (37%) 0.008
Absent 6/20 (68.4%)
Stage
IIIA1 2/13 (83.9%) 0.002
IIIA2, IIIB, IIIC 39/68 (37%)
Debulking
Maximal 6/27 (74.3%) < 0.001 0.37 0.16–0.86 0.021
Optimal 35/54 (30.1%)
a:5-year overall survival rate
Abbreviations: MOC Mucinous Ovarian Carcinoma, OS Overall Survival, LN
Lymph node, HR Hazard ratio, CI Confidence interval, y Years
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and OS as 18.0 and 45.0 months, respectively, for women
with stage III MOC who have undergone maximal or
optimal CRS. The corresponding figures were 29.0 and
101.0 months, respectively, for the serous counterpart.
There was no significant difference between the cases and
the controls in terms of PFS. However, women with MOC
were 2.3 times more likely to die of their tumors when
compared to patients with serous EOC in the current study.
Table 4 compares the findings of the current study with
those of previous studies.
Using the Surveillance, Epidemiology and End Results
(SEER) database, Schiavone et al. [7] reported that the
HR for OS was 1.60 for women with stage III MOC. The
5-year survival rate for women with stage III serous
EOC was 33.6% compared with 25.7% for MOC. The
corresponding rates were 66.3%, and 44.9%, respectively,
in our study. It should be emphasized that the SEER
database lacks several important variables such as extent
and outcome of initial surgery including the size of RD,
type of adjuvant chemotherapy, and recurrence. However,
all patients (cases and controls) in the current study under-
went maximal or optimal CRS followed by paclitaxel/carbo-
platin chemotherapy and cases were matched to controls in
terms of age, tumor grade, substage of disease, and extent
of RD.
Favorable prognostic factors such as younger patient
age, lower tumor grade, and less peritoneal carcinoma-
tosis have been reported for women with MOC [9, 22].
However, maximal cytoreduction was identified as the
sole independent prognostic factor for increased PFS
and OS in the current study. The volume of tumor left
after primary CRS depends on the number and the size
of the tumor elements [5]. We were not able to define
the number of lesions left after initial surgery in this
retrospective analysis. The maximal diameter of the lar-
gest residual tumor nodule is a very crude estimate of
RD [5, 23], but it still gave valuable prognostic informa-
tion in our study.
Melamed et al. [13] have recently reported that cytore-
duction to no gross RD is associated with a hazard reduc-
tion of 54% compared to any gross RD in MOCs.. The
optimal chemotherapy regimen for MOC has not been
clarified yet; so aggressive CRS seems to be the only effect-
ive treatment to improve the prognosis in advanced-stage
MOC [12]. Our finding associated with maximal cytore-
duction as the sole independent prognostic factor for both
PFS and OS in women with stage III MOC is in agree-
ment with previous reports [12, 13].
The most important limitation of the current study
is the fact that central pathology review was not per-
formed. There is now increasing recognition that
many MOCs may in fact be metastatic mucinous neo-
plasms from other primary sites [7]. Differentiating
MOC from gastrointestinal cancer [24, 25], mainly
carcinomas of appendix, and colorectal cancer by
morphology alone can be difficult. It should be
reminded that no patients receiving neoadjuvant
chemotherapy were included in the current study and
all patients have undergone surgical exploration which
commonly would have identified a cancer of gastro-
intestinal origin. Additionally, immunohistohemical
studies were performed in cases where metastatic tu-
mors could not be excluded. Recent data suggests
that the application of updated criteria results in reli-
able histopathological diagnoses based on the cell
type [26]. Nevertheless, our study was restricted by
the lack of a central pathology review as many previ-
ous reports [7, 13, 20, 27].
The major strength of the current study is the inclu-
sion of a relatively large number of patients with stage
III MOC. Our study has the advantage that all included
patients were treated with the standard paclitaxel/carbo-
platin regimen. The standard surgery and the standard
postoperative adjuvant chemotherapy regimen seem to
improve the reliability of our findings and decrease the
probable effects of the confounders.
Table 4 Comparison of the findings of the current study with those of previous studies associated with advanced mucinous ovarian
carcinoma
Author Number of women with MOC Stage of disease Extent of residual disease Median PFS (months) Media OS (months)
Hess, 2004 [18] 27 III, IV optimal or suboptimal 5.7 12.0
Pectasides, 2005 [27] 47 III, IV optimal or suboptimal 11.8 33.2
Winter, 2007 [19] 34 III optimal or suboptimal 10.5 14.8
Bamias, 2010 [8] 24 III, IV optimal or suboptimal NR 15.4
Mackay, 2010 [20] 264 III, IV optimal or suboptimal 7.6 14.6
Bamias, 2012 [21] 21 III, IV optimal or suboptimal NR 15.0
Karabuk, 2013 [14] 50 III, IV optimal or suboptimal 7.0 35.0
Current study 81 III maximal or optimal 18.0 45.0
Abbreviations: MOC mucinous ovarian carcinoma, PFS progression-free survival, OS overall survival, NR not reported
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We conclude that women with stage III MOC seem
to be 2.3 times more likely to die of their tumors when
compared to patients with serous EOC. Maximal
cytoreduction seems to be the sole independent prog-
nostic factor for increased OS in women with stage III
MOC. As the extent of RD is a modifiable prognostic
factor, it seems reasonable to perform maximal CRS
whenever possible in order to improve the outcomes
of those women.
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